Milan, Italy

Maurizio Meroni

This inventor holds 1 USPTO granted patent. Top assignee: Pharmacia & Upjohn. Active years: 2000.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Maurizio Meroni. Retrieved from https://idiyas.com/inventor/maurizio-meroni

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2000

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Maurizio Meroni: Innovator in Pharmaceutical Chemistry

Introduction

Maurizio Meroni is a notable inventor based in Milan, Italy. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds.

Latest Patents

Meroni holds a patent for "Heterocyclyl-ergoline derivatives as 5-HT.sub.1A receptor ligands." This innovative work focuses on creating new ligands that can interact with serotonin receptors, which are crucial in various neurological processes.

Career Highlights

He is currently employed at Pharmacia & Upjohn S.p.a., a company known for its advancements in pharmaceuticals. His work at this organization has allowed him to explore and develop new therapeutic options.

Collaborations

Meroni has collaborated with esteemed colleagues such as Sergio Mantegani and Tiziano Bandiera. These partnerships have fostered a creative environment that enhances the potential for groundbreaking discoveries.

Conclusion

Maurizio Meroni's contributions to pharmaceutical chemistry and his innovative patent highlight his role as a key figure in the industry. His work continues to influence the development of new therapeutic agents.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…